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ABSTRACT 25 
Background 26 
The issue of whether all incidental papillary thyroid microcarcinoma (PTMC) should be 27 
managed by early surgery (ES) has been questioned and there is a growing acceptance that a 28 
non-surgical approach (NSA) might be more appropriate. We conducted a cost-effectiveness 29 
analysis comparing the two strategies in managing incidental PTMC. 30 
Methods 31 
Our base case was a hypothetical 40 year-old female diagnosed with a unifocal intra-thyroidal 32 
9mm PTMC. The PTMC was considered suitable for either strategy. A Markov decision tree 33 
model was constructed to compare the estimated cost-effectiveness between ES and NSA after 34 
20 years. Outcome probabilities, utilities and costs were derived from the literature. The 35 
threshold for cost-effectiveness was set at USD50,000/quality-adjusted life year (QALY). A 36 
further analysis was done for patients <40 and ≥40 years. Sensitivity and threshold analyses were 37 
used to examine model uncertainty. 38 
Results 39 
Each patient who adopted NSA over ES cost an extra USD682.54 but gained an additional 0.260 40 
QALY. NSA was cost-saving (i.e. less costly and more effective) up to 16 years from diagnosis 41 
and remained cost-effective from 17 years onward. In the sensitivity analysis, NSA remained 42 
cost-effective regardless of patient age (<40 and ≥40 years), complications, rates of progression, 43 
year cycle and discount rate. In the threshold analysis, none of the scenarios that could have 44 
changed the conclusion appeared clinically likely.  45 
Conclusions 46 
 4 
For a selected group of incidental PTMC, adopting NSA was not only cost-saving in the initial 47 
16 years but also remained cost-effective thereafter. This was irrespective of patient age, 48 
complication rate or rate of PTMC progression.49 
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INTRODUCTION 50 
Papillary thyroid carcinoma (PTC) is the most common type of thyroid carcinoma and its age-51 
related incidence has doubled in the last two decades [1]. However, despite this rise, the 52 
associated mortality has remained largely unchanged [2,3]. One explanation for this is that this 53 
rise has been mainly due to an increased discovery of seemingly-harmless papillary thyroid 54 
microcarcinoma (PTMC) (≤1cm) rather than clinically-significant PTCs [2,3]. Autopsy studies 55 
have shown that occult PTMCs are present in up to one-third of patients who died of unrelated 56 
disease [4]. Therefore, most PTMCs probably never cause any harm or become clinically–57 
significant over one’s life-time. This has led to the question of whether all incidental PTMCs 58 
should be managed by immediate or early surgery (ES) in the same way as other larger PTCs. 59 
To date, two Japanese centers (namely, the Kuma Hospital and Cancer Institute Hospital) have 60 
challenged this conventional dogma by conducting non-surgical or observation trials for 61 
incidental PTMC for the last 10 years or more [5-8]. Under these trials, patients with 62 
cytologically-confirmed PTMC were continuously monitored by regular ultrasound (USG) 63 
examination and were offered ES only when the PTMC exhibited signs of progression or spread 64 
[5-8]. Their results so far have shown that the great majority (>90%) of PTMCs do not progress 65 
with time and more importantly, under the non-surgical approach (NSA), none of the patients 66 
developed distant metastasis or die from PTC as a result of delayed surgery [5-8]. Given these 67 
findings, NSA has been accepted and adopted by the Japanese Society of Thyroid Surgeons and 68 
Japan Association of Endocrine Surgeons as an alternative treatment of PTMC [9]. The 69 
feasibility of adopting a similar strategy has been increasingly discussed in the West [10,11]. 70 
However, while NSA may serve as an acceptable alternative to ES in the management of 71 
incidental PTMC, its cost-effectiveness has rarely been discussed. Although NSA may cost less 72 
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initially because of fewer operations and less procedural-related complications, it requires life-73 
time surveillance and also over time, more patients are expected to need surgery because of 74 
tumor progression. Therefore, we hypothesized that perhaps over time, NSA might become more 75 
costly and even less cost-effective than ES from an institution’s perspective. The present study 76 
aimed to compare the long-term cost-effectiveness between ES and NSA for cytologically-77 
confirmed incidental PTMC based on the published literature.78 
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MATERIALS AND METHODS 79 
A decision tree model using TreeAge Software Pro version 2013 (Treeage Software, Inc., 80 
Williamstown, MA, US) was constructed to compare the long-term cost-effectiveness between 81 
two strategies, namely NSA and ES, in the management of a cytologically-confirmed incidental 82 
PTMC. According to the observation trial protocol, after diagnosis, patients were continuously 83 
monitored half-yearly with USG examination until there were signs of tumor progression or 84 
spread [5-8]. These included the index tumor enlarging ≥ 3mm from its original size, new 85 
appearance of regional nodal metastasis confirmed on fine-needle aspiration cytology (FNAC) 86 
and / or the index PTMC enlarging to ≥ 12mm in size [5-8]. For the first and third scenarios, a 87 
hemithyroidectomy (HT) + unilateral central neck dissection (CND) was considered sufficient 88 
[5-8]. For the second scenario, a total thyroidectomy + unilateral central neck dissection + lateral 89 
selective neck dissection (TT+ CND + SND) was necessary because new nodal metastases were 90 
mostly found in the lateral compartment [5-8]. In addition, over time, some patients would 91 
undergo thyroidectomy for a non-cancerous cause (such as Graves’ disease, multinodular goiter 92 
or change in patient or physician preference) and in such situations, a TT + CND was usually 93 
performed [5,6]. In contrast, under the ES strategy, all patients underwent a HT + CND shortly 94 
after diagnosis. Figure 1 outlines the decision-analytic modelling. 95 
Base-case patient 96 
A 40 year-old female who was incidentally diagnosed with a unifocal intra-thyroidal 9mm 97 
PTMC in the right lobe. The diagnosis was confirmed on FNAC and the tumor was considered 98 
suitable for NSA because it was located far from the trachea or recurrent laryngeal nerve and 99 
there was no associated nodal or distant metastasis or history of previous thyroidectomy, familial 100 
syndrome or neck irradiation [5-8]. She was managed expectantly for 20 years.  101 
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Probabilities 102 
The proportions of PTMCs showing signs of progression or spread (such as interval size 103 
enlargement ≥3mm, development of new regional nodal metastasis and PTMC enlarging to 104 
≥12mm) and chance of needing thyroidectomy for a non-cancerous cause over 1 year were 105 
derived from data that had spanned for over 10 years [5-8]. Estimate on surgical complications 106 
after HT + CND, TT + CND and TT + CND + SND came from relevant studies in the literature 107 
[12-14]. Base-case values were derived by pooling the results of all retrieved studies. The annual 108 
mortality rate of female patients by 10-year age groups was quoted from the US Centers for 109 
Disease Control and Prevention [15]. Table 1 summarizes outcome probabilities used.  110 
Cost data 111 
Our model only looked at the cost of NSA and ES from an institution’s perspective. Total cost 112 
included procedural cost, complication cost, and hospitalization. Indirect costs such as loss of 113 
productivity and wages were not included. For simplicity, the life-time cost of thyroxin 114 
replacement was not included as the majority of operations were HT + CND. Unit costs of HT + 115 
CND, TT + CND and TT + CND + SND were estimated based on Medicare reimbursement for 116 
surgical procedure obtained from public access file from Centers for Medicare and Medicaid 117 
Services [16-18]. Unit costs of surgically-related complications and half yearly USG surveillance 118 
were based on data obtained from previous cost-effectiveness analyses [13,14].  Table 2 119 
summarizes the unit costs used.  120 
Effectiveness data 121 
Effectiveness was measured by quality-adjusted life years (QALYs) gained. QALY adjusts the 122 
life-expectancy through the multiplication of quality of life adjustment with duration stayed at 123 
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each health state. The quality of life adjustment is quantified by a utility score ranging from zero 124 
to one. Table 1 lists the utility score for each health state. 125 
Assumptions 126 
All surveillance USG examinations were performed by dedicated radiologists using standardized 127 
technique with minimal inter-observer variability. The proportion of PTMC showing signs of 128 
progression (such as tumor size enlargement, nodal appearance and tumor becoming ≥ 12mm) 129 
was assumed to be constant throughout the entire observation period and similar for patients of 130 
all ages. All patients in both strategies were assumed cured and disease-free after surgery (i.e. no 131 
locoregional recurrence) as these tumors are considered very low risk [19]. A permanent 132 
complication resulted from surgery was assumed to be the only factor to impair the health state 133 
of patients. Temporary complications and patient anxiety during observation were not accounted 134 
for. Full compliance was assumed for all kinds of assessment, treatment and surveillance.  135 
Base-case analysis 136 
This was done according to the established guideline for cost-effectiveness analysis [20]. The 137 
incremental cost-effectiveness ratio (ICER) was the only outcome measurement and equaled to 138 
[cost of NSA – cost of ES] / [QALYs of NSA – QALYs of ES]. A strategy was “cost-saving” if 139 
it was costing less and also more effective over the competing strategy (i.e. that strategy 140 
dominated the competing strategy). A strategy was regarded cost-effective over another strategy 141 
if the ICER was < USD50,000 per QALY gained. This threshold was chosen based on analysis 142 
of the cost of current healthcare resource allocation decisions in the US [20]. Since age was 143 
shown to be a critical determinant of tumor progression and spread [6], a subgroup analysis was 144 
done for those aged <40 years and those aged ≥40 years. 145 
Sensitivity analysis 146 
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Univariate sensitivity analysis was performed to evaluate the impact of various outcome 147 
probabilities on the base-case analysis. Each clinical parameter varied from the lowest to the 148 
highest values as suggested in the literature while other parameters remained constant. Since ES 149 
would be less effective than NSA (a positive incremental effectiveness), a negative incremental 150 
cost meant NSA was a dominant strategy. A threshold analysis was undertaken to capture the 151 
threshold clinical values at which the ICER of NSA relative to ES became zero (cost equivalence) 152 
or infinity (QALY equivalence). The range of threshold analysis was considerably expanded by 153 
adopting the theoretical range from 0 to 100%. 154 
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RESULTS 155 
Base-case analysis 156 
Table 3 shows the results of base-case analysis. After a 20-year period, each patient in NSA 157 
spent an extra USD682.54 but also gained an additional 0.260 QALY over ES. Therefore, 158 
following the base-case assumptions and model inputs, NSA became more costly but was also 159 
more effective than ES in the institution’s perspective. The ICER of USD2630.00 for NSA 160 
relative to ES was far below the recommended threshold of USD50,000 per QALY. In the 161 
subgroup analysis, those aged <40 years had an ICER which was higher than that of those aged 162 
≥40 years (USD 11501.750 vs. USD 1262.696). Nevertheless, both were still far below the 163 
threshold of USD 50,000 per QALY. 164 
Sensitivity analysis 165 
Table 3 shows the univariate sensitivity analysis. No change in the conclusion was observed 166 
when key parameters such as complication rates and annualized rate of progression under NSA 167 
varied. Varying these parameters still yielded positive incremental effectiveness and ICERs 168 
implying NSA remained cost-effective or cost-saving. Similarly, varying the number of year-169 
cycles (from 10 to 50 years) or discount rate (from 0 to 5%) did not change the base-case 170 
conclusion. The same analysis was performed for the two subgroups, patients <40 years and ≥40 171 
years, but again, despite varying complication rates, year cycle and discount rate, NSA remained 172 
cost-effective or cost saving (data not shown). Figure 2 shows the changes in average cost for 173 
NSA relative to ES over a 50-year period. Relative to ES, NSA was cost-saving up to 16 years 174 
and thereafter, became cost-effective.  175 
Table 4 shows the threshold analyses. To make NSA cost-saving relative to ES beyond 20 years, 176 
there were 2 possible scenarios. First, the permanent vocal cord palsy (VCP) after HT + CND 177 
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increased from 0.85% to ≥1.34%. Second, the hematoma rate after HT + CND increased from 178 
0.69% to ≥15.33%. In contrast, to render ES cost-saving relative to NSA, there were 5 possible 179 
but unlikely scenarios. They were permanent VCP after TT + CND increased from 1.70% to 180 
≥47.04%, annualized rate of tumor size enlargement increased from 0.84% to ≥88.74%, 181 
annualized rate of new nodal metastasis increased from 0.32 to ≥13.95%, annualized rate of 182 
becoming clinical disease increased from 0.73% to ≥88.62% and annualized rate of other 183 
indications for surgery increased from 1.03% to ≥14.65%. 184 
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DISCUSSION 185 
To our knowledge, this is the first study to examine the cost-effectiveness of adopting NSA in 186 
the management of incidental PTMC. Our data showed that adopting a strategy of NSA in a well 187 
selected group of PTMC was not only cost-saving (i.e. costing less) for the initial 16 years but 188 
also more cost-effective (i.e. ICER < USD50,000 per QALY) after 17 years than the ES strategy. 189 
However, this finding was not surprising because based on the pooled data, less than 3% of 190 
patients under the NSA strategy each year actually required ES (i.e. roughly 2% per year 191 
showing signs of tumor progression and 1% per year undergoing surgery for unrelated cause) 192 
whereas under the ES strategy, 100% of patients needed upfront surgery. Therefore, the initial 193 
cost of the ES strategy would be significantly higher than the NSA strategy. However, with the 194 
continuing half-yearly USG examination and the accumulative possibility of more costly “late” 195 
surgery and its related complications over time, our data showed that the NSA strategy became 196 
more costly over time. In fact, after 17 years, the NSA strategy became more expensive and its 197 
total cost continued to rise faster than that of ES (see Figure 2). Therefore, when only cost is 198 
considered, observation is only preferable for patients with advanced age or patients with a 199 
shortened (≤16 years) life-expectancy while ES is more preferable in younger and healthier 200 
patients (with long life-expectancy). 201 
However, in terms of effectiveness as measured by QALY gained, the NSA strategy was more 202 
effective than the ES strategy regardless of the length of observation. This was because the 203 
former resulted in less procedural-related permanent complications. In fact, in the sensitivity 204 
analysis, the incremental QALYs were always positive implying the fact that NSA was always 205 
more effective than ES regardless of surgical complications, rate of tumor progression, year 206 
cycle or discount rate. Furthermore, the range of ICERs was far below the threshold of USD 207 
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50,000 per QALY. Therefore, NSA was always the more cost-effective option. Even when the 208 
year cycle was extended to 50 years (i.e. to the time of death), the ICER was still far below the 209 
threshold (USD3098.83 per QALY). Therefore, contrary to our initial hypothesis, our study 210 
showed that observation was always going to be a cost-saving or cost-effective strategy in the 211 
management of incidental PTMC. 212 
From the threshold analyses, although there were 5 possible scenarios which could have rendered 213 
the ES strategy cost-saving when compared to NSA, they were clinically unlikely to happen 214 
because they all involved dramatically increasing the permanent VCP after TT + CND or 215 
annualized base rates of progression. For example, interval size enlargement increased by more 216 
than 100 times (from 0.84% to ≥88.74%) or appearance of nodal metastasis increased by more 217 
than 40 times (from 0.32% to ≥13.95%). Based on the current knowledge, these increases would 218 
seem unrealistic. 219 
However, despite these results, we do acknowledge several shortcomings. First, some of the 220 
assumptions were over-simplified. For example, although USG examination remains the best 221 
imaging modality for tumor surveillance and monitoring, it is generally more difficult to 222 
accurately measure the size of more posteriorly-located tumors and also tumors in a background 223 
of chronic thyroiditis [21]. These situations may lead to less reliable monitoring and lower the 224 
cost-effectiveness of the NSA strategy. Second, although the present model assumed a constant 225 
rate of progression and spread for all patients regardless of age and other clinicopathologic 226 
features, recent studies found young age [6] and pregnant patients [22,23] had greater chance of 227 
tumor progression and  therefore, these factors could potentially lower the cost-effectiveness of 228 
the NSA strategy. Third, despite a comprehensive literature search, selection biases could not be 229 
completely ruled out as all of these observation trials had been non-randomized. Perhaps, 230 
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patients who preferred NSA were also those who were less likely to progress or spread over time. 231 
Fourth, given that indirect costs such as loss of productivity and wages were not included, we 232 
believe their inclusion would have further favored NSA over ES. Last, despite the evidence that 233 
most PTMC do not progress or spread over time, when both NSA and ES were equally offered, 234 
the majority of patients and physicians might still prefer ES over NSA because of anxiety and 235 
uncertainty [5,6,10,11]. Therefore, perhaps the most effective way of lowering cost would be to 236 
adopt a policy of avoiding FNAC on nodules <10mm [24]. 237 
 238 
CONCLUSION 239 
In the institution’s perspective, NSA was cost-saving relative to ES in the first 16 years of 240 
diagnosis and thereafter, it continued to be a more cost-effective option than ES for a selected 241 
group of PTMC. This was regardless of patients aged <40 or ≥40 years. Although there were 5 242 
possible clinical scenarios which could have rendered ES as cost-saving compared to NSA, all 243 
seemed clinically unlikely as all involved a significant increase in the published rates of 244 
complication and signs of PTMC progression.245 
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Table 1. Literature-based probabilities 
Clinical Parameters Base-case 
(%) 
Range for sensitivity 
analysis (%) 
References 
Surgical complications  
- Temporary vocal cord palsy 
  - HT + CND 
  - TT + CND 
  - TT + CND + SND 
- Permanent vocal cord palsy 
  - HT + CND 
  - TT + CND 
  - TT + CND + SND 
- Temporary hypoparathyroidism 
   - TT + CND 
  - TT + CND + SND 
- Permanent hypoparathyroidism 
  - TT + CND 
  - TT + CND + SND 
- Hematoma formation 
  - HT + CND 
  - TT + CND 
  - TT + CND + SND 
- Chyle leakage 
  - TT + CND + SND 
 
 
1.64 
3.28 
3.28 
 
0.85 
1.70 
1.70 
 
20.64 
20.64 
 
1.47 
1.47 
 
0.69 
1.29 
1.79 
 
5.81 
 
 
0.00 – 3.63 
0.00 – 7.26 
0.00 – 7.26 
 
0.00 – 1.25 
0.00 – 2.51 
0.00 – 2.51 
 
8.70 – 42.86 
8.70 – 42.86 
 
0.00 – 5.88 
0.00 – 5.88 
 
0.00 – 1.50 
0.00 – 2.20 
0.00 – 2.50 
 
5.80 – 5.83 
 
 
25,26 
12-14 
12-14 
 
25,26 
12-14 
12-14 
 
12-14 
12-14 
 
12-14 
12-14 
 
12-14 
12-14 
12-14 
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Proportion of patients showing signs of 
progression in 1 year under NSA 
- Interval size enlargement (≥3mm) 
  - < 40 years old 
  - ≥ 40 years old 
- Appearance of nodal metastasis  
  - < 40 years 
 
 
0.84 
1.60 
0.81 
0.32 
1.04 
 
 
0.56 – 0.98 
1.60 
0.81 
0.18 – 0.38  
1.04 
 
 
5-8 
6 
6 
5-8 
6 
  - ≥ 40 years old 
- Clinical disease (tumor ≥12mm) 
  - < 40 years 
  - ≥ 40 years 
0.19 
0.73 
1.72 
0.52 
0.19 
0.68 – 0.78   
1.72 
0.52 
6 
5-8 
6 
6 
Other indications for surgery* 1.03 0.58 – 1.15 5,6 
Number of deaths per 1000 population 
- 40 – 44 
- 45 – 54 
- 55 – 64 
- 65 – 74 
- 75 – 84 
- 85+ 
 
1.4 
3.2 
6.4 
15.3 
41.4 
132.2 
 
15 
15 
15 
15 
15 
15 
Healthy state in model 
- Alive without permanent complication 
- Alive with permanent complication 
- Death 
Utility score 
1.00 
0.54 
0.00 
 
Assumption 
28 
Definition 
Abbreviations: HT + CND = Hemithyroidectomy + unilateral central neck dissection; TT + CND 
= Total thyroidectomy + unilateral central neck dissection; TT + CND + SND = Total 
thyroidectomy + unilateral central neck dissection + lateral selective neck dissection; NSA = 
non-surgical approach 
* such as patients who developed Grave’s disease or benign multinodular goiter or those who 
changed their preference (from NSA to ES) over time 
Table 2. Unit cost (USD) for each service component for post-thyroidectomy 
Cost component  Unit cost 
(USD) 
Reference 
Surgical procedure 
- Hemithyroidectomy + central neck dissection 
- Total thyroidectomy + central neck dissection 
- Total thyroidectomy + central neck dissection + selective neck 
dissection 
 
4513 
6013 
12495 
 
16-18 
16-18 
16-18 
Each visit with ultrasound examination 300 16-18 
Surgical complications  
- Temporary vocal cord palsy+ 
  - including consultation, laryngoscopy and speech therapy 
- Permanent vocal cord palsy# 
  - including consultations, laryngoscopy, speech and medialization 
- Temporary hypoparathyroidism+ 
  - including follow-up visits, blood tests and medications 
- Permanent hypoparathyroidism (annual cost)# 
  - Follow-up visits, blood tests, medications 
- Hematoma requiring neck re-exploration 
- Chyle leak* 
 
564 
 
10367 
 
144 
 
863 
 
5754 
15404 
 
16-18 
 
16-18 
 
16-18 
 
16-18 
 
16-18 
16-18 
+ assumed an average of 2-month duration 
# includes monthly visit for the first 6 months and then thereafter 6-monthly follow-up  
* assumed to be managed conservatively  
 
Table 3. Results of base-case and sensitivity analysis 
     Cost (in USD) per 
patient 
QALYs per patient ICER per patient 
Base-case Analysis 
  
Non-surgical approach (NSA) 
- < 40 years 
- ≥ 40 years 
7204.33 
8859.86 
6862.29 
15.228 
15.172 
15.238 
473.099 
  
Early surgery (ES) 
- < 40 years 
- ≥ 40 years 
6521.80 
6521.80 
6521.80 
14.968 
14.968 
14.698 
435.703 
  
Incremental (NSA – ES) 
- < 40 years 
- ≥ 40 years 
682.54 
2338.06 
340.50 
0.260 
0.203 
0.270 
2629.998 
11501.750 
1262.696 
Univariate Sensitivity Analysis 
Parameters Parameter Range (%) Range for Incremental QALYs Range for ICER 
Surgical complications  
 Temporary vocal cord palsy 
   HT + CND 0.00 – 3.63 0.260 0.260 2658.878 2594.955 
  TT + CND 0.00 – 7.26 0.260 0.260 2621.161 2640.721 
  TT + CND + SND 0.00 – 7.26 0.260 0.260 2627.238 2633.347 
 Permanent vocal cord palsy 
 
 
HT + CND 0.00 – 1.25 0.208 0.284 9003.492 428.543 
 
TT + CND 0.00 – 2.51 0.269 0.255 1720.515 3087.768 
 
TT + CND + SND 0.00 – 2.51 0.263 0.258 2338.726 2771.194 
 Temporary hypoparathyroidism 
 
 
TT + CND 8.70 – 42.86 0.260 0.260 2621.785 2645.283 
 
TT + CND + SND 8.70 – 42.86 0.260 0.260 2627.433 2634.772 
Permanent hypoparathyroidism 
 
 
TT + CND 0.00 – 5.88 0.268 0.234 2488.558 3115.279 
 
TT + CND + SND 0.00 – 5.88 0.262 0.252 2584.851 2771.097 
Hematoma formation 
 
 
HT + CND 0.00 – 1.50 0.260 0.260 2753.961 2484.476 
 
TT + CND 0.00 – 1.90 0.260 0.260 2694.539 2646.765 
 
TT + CND + SND 0.00 – 2.50 0.260 0.260 2614.632 2636.093 
 Chyle leakage 
 
  TT + CND + SND 5.80 – 5.83 0.260 0.260 2629.768 2630.458 
Proportion of patients showing signs of progression or 
spread in the NSA strategy 
 
  
Interval size enlargement 
(≥3mm) 0.56 – 0.98 0.266 0.256 2072.152 2906.217 
  Appearance of nodal metastasis  0.18 – 0.38 0.265 0.257 1679.260 3032.938 
  Clinical disease (tumor ≥12mm) 0.68 – 0.78 0.261 0.258 2530.663 2729.381 
Other indications for surgery* 0.58 – 1.15 0.275 0.255 1193.891 3042.330 
Year Cycle 10 to 50 years 0.077 1.397 Favors NSA 3098.831 
Discount rate 0 to 5 0.376 0.206 6496.645 Favors NSA 
Abbreviations: QALYs = Quality-adjusted life-years; ICER = Incremental cost-effectiveness ratio; HT + CND = hemithyroidectomy 
+ central neck dissection; TT + CND = total thyroidectomy + central neck dissection; TT + CND + SND = total thyroidectomy + 
central neck dissection + lateral selective neck dissection 
* such as Grave’s disease, benign multinodular goiter or change in patient or clinician preference  
 
Table 4. Threshold analyses with ICER becoming zero or infinity 
Parameters Base-case 
(%) 
Threshold 
values (%) at 
ICER=0 / 
infinity 
Values (%) at 
ICER>0 
Values at which 
NSA became cost-
saving 
Values at which 
ES became cost-
saving 
Complications  
Permanent vocal cord palsy after 
HT+CND 
0.85 1.34 0.00 to 1.34 1.34 to 100.00 NA 
Permanent vocal cord palsy after 
TT+CND 
1.70 47.04 0.00 to 47.04 NA 47.04 to 100.00 
Hematoma formation after HT+CND 0.69 15.33 0.00 to 15.33 15.33 to 100.00 NA 
Proportion of patients showing signs of progression under NSA  
  Interval size enlargement (≥3mm) 0.84 88.74 0.00 to 88.74 NA 88.74 to 100.00 
  Appearance of nodal metastasis  0.32 13.95 0.00 to 13.95 NA 13.95 to 100.00 
  Clinical disease (tumor ≥ 12mm) 0.73 88.62 0.00 to 88.62 NA 88.62 to 100.00 
Other indications for surgery* 1.03 14.65 0.00 to 14.65 NA 14.65 to 100.00 
Year cycle 20 17 17 to 50 1 to 16 NA 
Discount rate 3.00 4.60 0.00 to 4.60 4.60 to 5.00 NA 
Abbreviations: HT + CND = Hemithyroidectomy + central neck dissection; TT + CND = total thyroidectomy + central neck 
dissection; ICER = incremental cost-effectiveness ratio; NA = not applicable 
* such as Grave’s disease, benign multinodular goiter or change in patient or clinician preference  
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